Clinicians Battle GLP-1 Weight Loss Misinformation
Most clinicians correct false claims about GLP-1 drugs weekly, with social media cited as a major source.
Updated on Nov. 3, 2026 in Weight Loss
Live Poll
Do you trust health information you see on social media?
A survey finds 73 per cent of clinicians must correct misinformation about GLP-1 weight loss drugs at least once a week, and one in five corrects it daily. Novo Nordisk has separately sought a website-blocking order against six UK internet service providers targeting counterfeit GLP-1 sellers.
Why it matters
Misleading claims about GLP-1 drugs can steer patients toward counterfeit products or unsafe telehealth offers. The problem is widespread enough that it is now routinely affecting clinical consultations.
A clinician survey found 73% of respondents correct GLP-1 misinformation at least weekly and 20% daily, with 59% naming TikTok as a source. The survey's sample size and methodology were not reported, and the scale of misinformation beyond clinicians' own experience remains unmeasured.
The players
Novo Nordisk
Novo Nordisk is a Danish pharmaceutical company that manufactures GLP-1 drugs including semaglutide, which is sold under the brand names Ozempic and Wegovy.
U.S. Food and Drug Administration (FDA)
The FDA is the U.S. federal agency responsible for regulating drugs, medical devices and drug advertising, including telehealth promotions.
The details
Clinicians cite TikTok, friends and family, Facebook, celebrity or influencer endorsements, Instagram and YouTube as sources of false claims. Separately, Novo Nordisk asked six UK internet service providers to block sites operated by Viogen Pharma, Pharma-Labs, Leo Labs and The Steroid Supplier, while the FDA issued thousands of warning letters to telehealth companies over six months for misleading GLP-1 ads.
Timeline
Over a six-month period, the FDA issued thousands of warning letters to telehealth companies over misleading GLP-1 ads.
Earlier this year, researchers found health influencers exaggerate benefits and omit alternatives.
Novo Nordisk recently applied for a UK website-blocking order against counterfeit sellers.
Health Landscape
The FDA's six-month campaign of warning letters to telehealth companies over misleading GLP-1 ads shows regulators acting against advertising at the source. The clinician survey suggests that enforcement has not yet reduced the volume of false claims reaching patients through social media.
Patients weighing GLP-1 drugs should check whether a prescribing telehealth service is verified before buying. Counterfeit sellers and misleading ads are the specific risks flagged in this coverage.
The takeaway
Verify GLP-1 claims with a licensed clinician rather than social media posts or influencer endorsements. Misinformation is common enough that asking a prescriber directly is a practical safeguard.
Further reading
For more on the drugs at the center of this debate, see Weight Loss coverage.
Source note: This article includes information reported by Forbes.
Live Poll
Do you trust health information you see on social media?
